{"organizations": [], "uuid": "703c27faa36a67d4b73d220d74c0e7bbd4c2658c", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180227.html", "section_title": "Archive News &amp; Video for Tuesday, 27 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-heron-therapeutics-qtrly-net-loss/brief-heron-therapeutics-qtrly-net-loss-per-share-1-09-idUSASB0C7TR", "country": "US", "domain_rank": 408, "title": "BRIEF-Heron Therapeutics Qtrly Net Loss Per Share $1.09", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.444, "site_type": "news", "published": "2018-02-28T06:24:00.000+02:00", "replies_count": 0, "uuid": "703c27faa36a67d4b73d220d74c0e7bbd4c2658c"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-heron-therapeutics-qtrly-net-loss/brief-heron-therapeutics-qtrly-net-loss-per-share-1-09-idUSASB0C7TR", "ord_in_thread": 0, "title": "BRIEF-Heron Therapeutics Qtrly Net Loss Per Share $1.09", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "heron therapeutics inc", "sentiment": "negative"}, {"name": "thomson reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 27 (Reuters) - Heron Therapeutics Inc:\n* HERON THERAPEUTICS ANNOUNCES FINANCIAL RESULTS FOR THE THREE AND TWELVE MONTHS ENDED DECEMBER 31, 2017 AND RECENT CORPORATE PROGRESS\n* QTRLY BASIC AND DILUTED NET LOSS PER SHARE $1.09 * QTRLY NET PRODUCT SALES $10.1 MILLION VERSUS $1.3 MILLION\n* Q4 EARNINGS PER SHARE VIEW $-0.79, REVENUE VIEW $9.3 MILLION -- THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-28T06:24:00.000+02:00", "crawled": "2018-02-28T13:12:10.011+02:00", "highlightTitle": ""}